Table 1.
Summary of selected studies using topotecan-based therapy for patients with relapsed/refractory Ewing sarcoma.
| Author [Ref] | N | Topotecan dose and schedule | Other drugs | Response Rate (complete + partial) | Comments |
|---|---|---|---|---|---|
| Hawkins et al. [10] | 20 | 0.3 mg/m2/d for 21-day continuous infusion | — | 10% | |
| Blaney et al. [9] |
3 | 1–1.3 mg/m2/d for 72-hour continuous infusion | — | 4% | |
| Bernstein et al. [12] | 36 | 2 mg/m2/d × 5 | — | 8% | Given as upfront window for 6 weeks in newly diagnosed metastatic patients |
| Bernstein et al. [12] | 37 | 0.75 mg/m2/d × 5 | CPM 250 mg/m2/d × 5 | 57%* | Given as upfront window for 6 weeks in newly diagnosed metastatic patients |
| Saylors et al. [13] | 17 | 0.75 mg/m2/d × 5 | CPM 250 mg/m2/d × 5 | 35% | 50% of patients received at least 6 courses before progression |
| Hunold et al. [14] | 49 | 0.75 mg/m2/d × 5 | CPM 250 mg/m2/d × 5 | 33% | Additional 26% with stable disease |
*In newly diagnosed patients with metastatic disease; CPM, cyclophosphamide.